When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Belimumab - Wikipedia

   en.wikipedia.org/wiki/Belimumab

   Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.

3. Lupus nephritis - Wikipedia

   en.wikipedia.org/wiki/Lupus_nephritis

   Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases.

4. Biogen-UCB's lupus drug meets main goal of late-stage trial - AOL

   www.aol.com/news/biogen-ucbs-lupus-drug-meets...

   Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...

5. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Belimumab: GlaxoSmithKline: active lupus nephritis [1] Osimertinib: AstraZeneca: adjuvant therapy after tumor resection in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations Ansuvimab: Ridgeback Biotherapeutics: Ebola Zaire

6. Diffuse proliferative nephritis - Wikipedia

   en.wikipedia.org/.../Diffuse_proliferative_nephritis

   The cause of diffuse proliferative glomerulonephritis (DPGN) depends on the severity of the disease. DPGN is a secondary disease, in that a disease that a patient already has causes DPGN to occur. The most common associated disease of DPGN is severe systemic lupus erythematosus(SLE). [4] Specifically, Lupus nephritis class IV. [5]

7. Liz Lightstone - Wikipedia

   en.wikipedia.org/wiki/Liz_Lightstone

   She has explored other therapeutics, including voclosporin and belimumab. [9] Alongside development new treatment strategies, Lightstone searched for urine biomarkers that could be indicative of the outcome of lupus nephritis. [10]